A detailed history of Price T Rowe Associates Inc transactions in Meira G Tx Holdings PLC stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,717 shares of MGTX stock, worth $74,012. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,717
Previous 11,806 7.72%
Holding current value
$74,012
Previous $50,000 8.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.88 - $5.23 $3,534 - $4,764
911 Added 7.72%
12,717 $54,000
Q2 2024

Aug 14, 2024

BUY
$4.21 - $5.81 $49,703 - $68,592
11,806 New
11,806 $50,000
Q1 2023

May 15, 2023

SELL
$5.04 - $8.6 $1.95 Million - $3.33 Million
-387,298 Reduced 54.71%
320,674 $1.66 Million
Q4 2022

Feb 14, 2023

SELL
$5.8 - $8.98 $3.17 Million - $4.91 Million
-547,094 Reduced 43.59%
707,972 $4.62 Million
Q3 2022

Nov 14, 2022

SELL
$7.55 - $11.25 $4.05 Million - $6.03 Million
-536,225 Reduced 29.94%
1,255,066 $10.6 Million
Q2 2022

Aug 15, 2022

SELL
$6.8 - $14.23 $120,128 - $251,387
-17,666 Reduced 0.98%
1,791,291 $13.6 Million
Q1 2022

May 16, 2022

SELL
$13.42 - $23.38 $2.84 Million - $4.95 Million
-211,788 Reduced 10.48%
1,808,957 $25.1 Million
Q4 2021

Feb 14, 2022

BUY
$12.78 - $23.74 $226,525 - $420,791
17,725 Added 0.88%
2,020,745 $48 Million
Q3 2021

Nov 15, 2021

SELL
$11.73 - $16.08 $39,236 - $53,787
-3,345 Reduced 0.17%
2,003,020 $26.4 Million
Q2 2021

Aug 16, 2021

SELL
$12.85 - $16.2 $448,824 - $565,833
-34,928 Reduced 1.71%
2,006,365 $31.1 Million
Q1 2021

May 17, 2021

SELL
$13.84 - $17.8 $34,143 - $43,912
-2,467 Reduced 0.12%
2,041,293 $29.5 Million
Q4 2020

Feb 16, 2021

BUY
$12.4 - $17.6 $25.3 Million - $36 Million
2,043,760 New
2,043,760 $30.9 Million

Others Institutions Holding MGTX

About MeiraGTx Holdings plc


  • Ticker MGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,010,700
  • Market Cap $262M
  • Description
  • MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative dise...
More about MGTX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.